Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor

Blood

Volumn 126, Issue 9, 2015, Pages 1095-1105

  Sugata, Kenji ^a,b   Yasunaga, Jun Ichirou ^a   Mitobe, Yuichi ^a   Miura, Michi ^a   Miyazato, Paola ^a   Kohara, Michinori ^c   Matsuoka, Masao ^a  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HBZ[157-176]; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PEPTIDE; PEPTIDE VACCINE; TAX PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN; RECOMBINANT VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN T-LYMPHOTROPIC VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; INFLAMMATORY DISEASE; LYMPHOMA CELL; MACACA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SPLEEN CELL; T CELL LEUKEMIA; TRANSGENIC MOUSE; VACCINATION; VACCINIA VIRUS; VIRUS CELL INTERACTION; VIRUS RECOMBINANT; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CHEMISTRY; IMMUNOLOGY; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MOLECULAR GENETICS; SCID MOUSE; TUMOR CELL LINE; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL LINE, TUMOR; GENE PRODUCTS, TAX; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MACACA MULATTA; MICE, INBRED C57BL; MICE, SCID; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL PROTEINS;

EID: 84942465621     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-04-641118     Document Type: Article

References (44)

1. Gallo RC. The discovery of the first human retrovirus: HTLV-1 and HTLV-2. Retrovirology. 2005;2(1):17.
2. Takatsuki K. Discovery of adult T-cell leukemia. Retrovirology. 2005;2:16.
3. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7(4):270-280.
4. Igakura T, Stinchcombe JC, Goon PK, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science. 2003;299(5613):1713-1716.
5. Takemoto S, Matsuoka M, Yamaguchi K, Takatsuki K. A novel diagnostic method of adult T-cell leukemia: monoclonal integration of human T-cell lymphotropic virus type I provirus DNA detected by inverse polymerase chain reaction. Blood. 1994;84(9):3080-3085.
6. Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol. 1995;69(5):2863-2868.
7. Bangham CR, Cook LB, Melamed A. HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection. Semin Cancer Biol. 2014;26:89-98.
8. Taylor GP, Goon P, Furukawa Y, et al. Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial. Retrovirology. 2006;3:63.
9. Treviño A, Parra P, Bar-Magen T, Garrido C, de Mendoza C, Soriano V. Antiviral effect of raltegravir on HTLV-1 carriers. J Antimicrob Chemother. 2012;67(1):218-221.
10. Afonso PV, Mekaouche M, Mortreux F, et al. Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. Blood. 2010;116(19):3802-3808.
11. Bangham CR. CTL quality and the control of human retroviral infections. Eur J Immunol. 2009;39(7):1700-1712.
12. Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene. 2011;30(12):1379-1389.
13. Grassmann R, Aboud M, Jeang KT. Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene. 2005;24(39):5976-5985.
14. Zhi H, Yang L, Kuo YL, Ho YK, Shih HM, Giam CZ. NF-κB hyper-activation by HTLV-1 tax induces cellular senescence, but can be alleviated by the viral anti-sense protein HBZ. PLoS Pathog. 2011;7(4):e1002025.
15. Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA. 2006;103(3):720-725.
16. Satou Y, Yasunaga J, Zhao T, et al. HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog. 2011;7(2):e1001274.
17. Sugata K, Satou Y, Yasunaga J, et al. HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines. Blood. 2012;119(2):434-444.
18. Miyazato P, Matsuoka M. Human T-cell leukemia virus type 1 and Foxp3 expression: viral strategy in vivo. Int Immunol. 2014;26(8):419-425.
19. Yamamoto-Taguchi N, Satou Y, Miyazato P, et al. HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression. PLoS Pathog. 2013;9(9):e1003630.
20. Gaudray G, Gachon F, Basbous J, Biard-Piechaczyk M, Devaux C, Mesnard JM. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol. 2002;76(24):12813-12822.
21. Takeda S, Maeda M, Morikawa S, et al. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer. 2004;109(4):559-567.
22. Macnamara A, Rowan A, Hilburn S, et al. HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog. 2010;6(9):e1001117.
23. Suemori K, Fujiwara H, Ochi T, et al. HBZ is an immunogenic protein, but not a target antigen for human T-cell leukemia virus type 1-specific cytotoxic T lymphocytes. J Gen Virol. 2009;90(Pt 8):1806-1811.
24. Enose-Akahata Y, Abrams A, Massoud R, et al. Humoral immune response to HTLV-1 basic leucine zipper factor (HBZ) in HTLV-1-infected individuals. Retrovirology. 2013;10:19.
25. Narita T, Ishida T, Masaki A, et al. HTLV-1 bZIP factor-specific CD4 T cell responses in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation. J Immunol. 2014;192(3):940-947.
26. Hilburn S, Rowan A, Demontis MA, et al. In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome. J Infect Dis. 2011;203(4):529-536.
27. Sekiguchi S, Kimura K, Chiyo T, et al. Immunization with a recombinant vaccinia virus that encodes nonstructural proteins of the hepatitis C virus suppresses viral protein levels in mouse liver. PLoS ONE. 2012;7(12):e51656.
28. Smith MR, Greene WC. Identification of HTLV-I tax trans-activator mutants exhibiting novel transcriptional phenotypes. Genes Dev. 1990;4(11):1875-1885.
29. Zhao T, Satou Y, Sugata K, et al. HTLV-1 bZIP factor enhances TGF-β signaling through p300 coactivator. Blood. 2011;118(7):1865-1876.
30. Harty JT, Badovinac VP. Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol. 2008;8(2):107-119.
31. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Trends Microbiol. 2000;8(9):410-418.
32. Rouse BT, Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol. 2010;10(7):514-526.
33. Shida H, Tochikura T, Sato T, et al. Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. EMBO J. 1987;6(11):3379-3384.
34. Ibuki K, Funahashi SI, Yamamoto H, et al. Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene. J Gen Virol. 1997;78(Pt 1):147-152.
35. Ohashi T, Hanabuchi S, Kato H, et al. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine. J Virol. 2000;74(20):9610-9616.
36. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837-842.
37. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8(5):351-360.
38. Patronov A, Doytchinova I. T-cell epitope vaccine design by immunoinformatics. Open Biol. 2013;3(1):120139.
39. Rowan AG, Suemori K, Fujiwara H, et al. Cytotoxic T lymphocyte lysis of HTLV-1 infected cells is limited by weak HBZ protein expression, but non-specifically enhanced on induction of Tax expression. Retrovirology. 2014;11(1):116.
40. Rende F, Cavallari I, Corradin A, et al. Kinetics and intracellular compartmentalization of HTLV-1 gene expression: nuclear retention of HBZ mRNAs. Blood. 2011;117(18):4855-4859.
41. Toulza F, Nosaka K, Takiguchi M, et al. FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-cell leukemia. Int J Cancer. 2009;125(10):2375-2382.
42. Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA. 2013;110(44):17945-17950.
43. Tourdot S, Scardino A, Saloustrou E, et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol. 2000;30(12):3411-3421.
44. Yamazaki J, Mizukami T, Takizawa K, et al. Identification of cancer stem cells in a Tax-transgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma. Blood. 2009;114(13):2709-2720.